Novartis AG (NVS) is a publicly traded Healthcare sector company. As of July 6, 2026, NVS trades at $155.27 with a market cap of $305.10B and a P/E ratio of 0.00. NVS moved -2.98% today. Year to date, NVS is +15.27%; over the trailing twelve months it is +29.15%. Its 52-week range spans $96.06 to $170.46. Analyst consensus is buy with an average price target of $171.59. Rallies surfaces NVS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Novartis to Acquire Myricx Bio in $1.5B Deal for NMTi ADC Platform: Novartis has agreed to acquire UK-based Myricx Bio in a deal valued at up to $1.5 billion, comprising a $1.1 billion upfront payment and up to $400 million in milestones. The acquisition grants Novartis rights to Myricx’s NMTi-based ADC payload platform, with lead candidates targeting B7-H3 and HER2 in solid tumors.
| Metric | Value |
|---|---|
| Price | $155.27 |
| Market Cap | $305.10B |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 4.74% |
| 52-Week High | $170.46 |
| 52-Week Low | $96.06 |
| Volume | 1.10M |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
3 analysts cover NVS: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $171.59.